Frontida BioPharm is a CDMO launched by founding management team members of Frontage Laboratories. Frontida offers the capability to manufacture Highly Potent Active Ingredient products, Combination Products, as well as DEA schedules II – V products. The company’s Duragran® granulation process eliminates the need for traditional extrusion and compaction manufacturing steps. Its AdaptDose™ technology platform can eliminate the need to reformulate after Phase I and reduces technical hurdles in the development and scale up processes. The company specialties include GMP commercial manufacture of oral solid dosages, oral liquids & suspensions, Mini-tablets, fixed dosage combinations and solvent granulations & coating. While Frontage and Frontida remain affiliates, they are separate business entities.